Total
0
Shares
Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ShareRoot has announced a two-for-three entitlement offer to raise roughly $950,000 to support a restructuring of the business into the digital healthcare industry
  • Almost one billion new shares will be issued at 0.1 cents per share and company directors have committed to taking part in the offer
  • This is the second re-branding of the company since it was founded in 2013
  • ShareRoot has cut costs by 40 per cent this year and has forecasted revenue for this financial year to reach a 90 per cent increase from last year
  • Company shares currently trade for 0.1 cents in a market cap of $1.57 million

ShareRoot is set to raise roughly $950,000 to support a restructuring of its business into a digital healthcare industry.

The company expects the two-for-three non-renounceable entitlement offer to provide enough money to drive a profitable business in the near term. Under the terms of the offer, almost one billion new shares will be issued at 0.1 cents per share, and company directors have committed to taking part in the offer.

Founded in 2013, the company initially focused on helping brands advertise on Pinterest. Since then, the company’s focus has changed. In 2014, ShareRoot rebranded itself as a legal-rights management and marketing platform.

Providing marketing data and a privacy protection ecosystem, ShareRoots served major clients like Johnson&Johnson, McDonald’s and Costco.

Now, the company has announced it is one again restructuring and has a “clear path forward” to success in the digital healthcare industry.

ShareRoot has seen no change to its share price of only 0.1 cents this year, but management spoke confidently to investors in an ASX release today and said it has already kicked several crucial goals for 2019.

Among these is a new leadership team with experience in health, marketing and technology, a financial restructuring and subsequent costs reduction, and a new technology pipeline designed to service biopharma, health and medtech markets.

The company says it has shut down most of its US operations and reduced staff numbers to effectively cut costs by 40 per cent. On top of this, ShareRoot management has forecast revenue for this financial year to reach a 90 per cent increase from last year.

ShareRoot CEO Michelle Gallaher said the company has found itself in an uphill battle, and its challenges over the past five months have sparked ShareRoots’ transformation.

“The company now has a technology pipeline loaded with four competitive opportunities to capture a leading edge in the global digital healthcare sector,” Michelle said.

“What we are developing is a unique convergence of artificial intelligence, real world healthcare data and social media, one of the most exciting new frontiers in the escalating digital transformation taking place in health,” she said.

ShareRoot shares remain unchanged today and continue to trade for 0.1 cents in a market cap of $1.57 million.

SRO by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.